ISREC – Swiss Institute for Experimental Cancer Research

Drug combo breaks down cancer resistance to immunotherapy

Published:13.01.23 — By combining a checkpoint inhibitor with a new immunocytokine, scientists at EPFL, Ludwig Institute for Cancer Research, CHUV and Roche have made a breakthrough in fighting against immunotherapy-resistant cancers.

The protein behind immunotherapy resistance

Published:18.11.22 — Scientists at EPFL, Ludwig Institute of Cancer Research, and CHUV have identified a key protein that helps tumors evade attacks by the immune system, contributing to poor responses to immunotherapy in the clinic.

Can Aztekin receives Branco Weiss Fellowship

Published:06.09.22 — The Branco Weiss Fellowship-Society in Science has selected ELISIR Scholar Dr Can Aztekin at EPFL as one of its new Fellows in 2022.